Gemini Therapeutics shares are trading higher after Goldman Sachs initiated coverage on the stock with a Buy rating and announced a price target of $20 per share. Gemini Therapeutics, a new precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases, today announced that it has completed a $42.5 million Series A financing to advance multiple programs into the clinic. Gemini Therapeutics news and GMTX price. Gemini Therapeutics is a clinical stage precision medicine company developing innovative treatments for age-related macular degeneration (AMD) by … Highly Speculative. Free real-time prices, trades, and chat. Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD). Gemini Therapeutics, a new precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases, announced that it has completed a $42.5 million Series A financing to advance multiple programs into the clinic. Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at … Gemini Therapeutics announced the completion of enrollment in its phase 2a “ReGAtta” study. Sector Healthcare RiskRating. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Gemini Therapeutics against related stocks people … View real-time stock prices and stock quotes for a full financial overview. GMTX - Gemini Therapeutics Inc Share News. Gemini is evaluating GEM103, a recombinant, hum Gemini Therapeutics, Inc., (Nasdaq: GMTX) a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Brian Piekos has been appointed to serve as … ReGAtta is a dose escalation trial of GEM103, a recombinant human complement factor H (CFH), in dry AMD patients with CFH loss-of-function gene variants. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined AMD, today announced the commencement of a Phase 2a trial advancing GEM103 as a potential add-on therapy for patients suffering from wet AMD who have, or may be at risk for, macular atrophy (MA) but require ongoing anti … The trial will advance GEM103 as a potential add-on therapy to anti-vascular endothelial growth factor (anti-VEGF) treatment. Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD). Photo courtesy of Gemini. Announces Effectiveness of Registration Statement for Proposed Business Combination with Gemini Special Meeting Scheduled for February 3, 2021 SAN FRANCISCO--(BUSINESS WIRE)--FS Development Corp announced today that its registration statement on Form S-4 has been declared effective by the SEC. Gemini Chief Executive Officer Jason Meyenburg pictured above. $12.95 0.3 2.7% Last Trade - 18/02/21. Gemini Therapeutics News & Media FS Development Corp. Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (“AMD”). GMTX | Complete Gemini Therapeutics Inc. stock news by MarketWatch. Biotech Gemini Therapeutics sinks 7.6% on first trading day, but CEO says it’s still a good stock Feb. 08, 2021 9:29 PM ET FS Development Corp. (FSDC) By: Jerry Kronenberg , SA News Editor Gemini Therapeutics Appoints Dr. Tuyen Ong as Independent Director - Ophthalmology innovator brings more than 20 years of clinical and drug development experience to … Get Gemini Therapeutics Inc (GMTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Gemini Therapeutics has commenced a Phase IIa trial of GEM103 for patients with wet age-related macular degeneration (AMD) who have or may be at risk of macular atrophy (MA). Community-created profile of Gemini Therapeutics in Cambridge, MA including executive profiles, news and insights, videos and contact information. Gemini Therapeutics Inc (NASDAQ: GMTX) concludes enrollment in its Phase 2a ReGAtta study evaluating GEM103, a recombinant human complement factor H … Topio Networks is the definitive source of curated information on millions of companies, people and industries." Get breaking ophthalmic news, device and drug updates, clinical trial coverage, thought-leader perspective, and industry announcements. Gemini Therapeutics on LinkedIn, Twitter & YouTube. Company profile page for Gemini Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information View the real-time GMTX price chart on Robinhood and decide if you want to buy or sell commission-free. Gemini Therapeutics on Wikipedia, Google News & Yahoo Finance. Our research pipeline is designed to develop treatments for genetically defined subpopulations of patients suffering from dry AMD and linked diseases. The combined company will be called Gemini Therapeutics, Inc. and will trade under the ticker symbol GMTX. Gemini Therapeutics announced the commencement of a phase 2a trial advancing GEM103 as a potential add-on therapy for patients suffering from wet AMD who have, or may be at risk for, macular atrophy (MA) but require ongoing anti-vascular endothelial growth factor (anti-VEGF) treatment. Gemini Therapeutics is now trading on the Nasdaq Exchange following its merger with FS Development Corp., a special purpose acquisition company (SPAC) sponsored by Foresite Capital. Company profile page for Gemini Therapeutics Sub Inc including stock price, company news, press releases, executives, board members, and contact information Gemini Therapeutics is a precision medicine company developing new drugs for age-related macular degeneration ("AMD") along with retinal disease in general and systemic diseases driven by complement. Latest news about Gemini Therapeutics. Gemini Therapeutics announced that GEM103, the company’s investigational treatment for dry AMD, has been granted Fast Track designation by the FDA. Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD). Get the latest Gemini Therapeutics (GMTX) stock price quote with real-time news, financials, charts and other important investing information. Gemini Therapeutics has 1,519 competitors including Express Scripts (United States (USA)), UnitedHealth Group (United States (USA)) and Iqvia (United States (USA)).